Abstract | BACKGROUND:
Mucopolysaccharidosis type II ( Hunter syndrome, or MPS II) is an X-linked lysosomal disorder caused by the deficiency of iduronate-2-sulfatase, which leads to the accumulation of glycosaminoglycans (GAGs) in a variety of tissues, resulting in a multisystemic disease that can also impair the central nervous system (CNS). OBJECTIVE: This review focuses on providing the latest information and expert opinion about the therapies available and under development for MPS II. METHODS: RESULTS AND DISCUSSION: Intravenous ERT is a well-established specific therapy, which ameliorates the somatic features but not the CNS manifestations. Intrathecal or intracerebroventricular ERT and intravenous ERT with fusion proteins, presently under development, seem to be able to reduce the levels of GAGs in the CNS and have the potential of reducing the impact of the neurological burden of the disease. Gene therapy and/or genome editing have shown promising results in preclinical studies, bringing hope for a "one-time therapy" soon. Results with HSCT in MPS II are controversial, and small molecules could potentially address some disease manifestations. In addition to the specific therapeutic options, supportive care plays a major role in the management of these patients. CONCLUSION: At this time, the treatment of individuals with MPS II is mainly based on intravenous ERT, whereas HSCT can be a potential alternative in specific cases. In the coming years, several new therapy options that target the neurological phenotype of MPS II should be available.
|
Authors | Francyne Kubaski, Filippo Vairo, Guilherme Baldo, Fabiano de Oliveira Poswar, Amauri Dalla Corte, Roberto Giugliani |
Journal | Current pharmaceutical design
(Curr Pharm Des)
Vol. 26
Issue 40
Pg. 5100-5109
( 2020)
ISSN: 1873-4286 [Electronic] United Arab Emirates |
PMID | 33138761
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Copyright | Copyright© Bentham Science Publishers; For any queries, please email at [email protected]. |
Chemical References |
- Glycosaminoglycans
- Iduronate Sulfatase
|
Topics |
- Enzyme Replacement Therapy
- Glycosaminoglycans
(therapeutic use)
- Humans
- Iduronate Sulfatase
(genetics, therapeutic use)
- Mucopolysaccharidosis II
(drug therapy, genetics)
- Phenotype
|